JP Morgan Maintains Overweight on SpringWorks Therapeutics, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on SpringWorks Therapeutics and raised the price target from $64 to $68.
September 04, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has maintained an Overweight rating on SpringWorks Therapeutics and increased the price target from $64 to $68, indicating a positive outlook.
The increase in price target from $64 to $68 by JP Morgan suggests a positive outlook for SpringWorks Therapeutics, likely leading to a short-term increase in stock price. The Overweight rating indicates confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100